Virtual consultation for red eye

Ho, Charlotte Shan; Avery, Anthony; Livingstone, Iain A. T.; Ting, Darren Shu Jeng

doi:10.1136/bmj.n1490

Cited by 5 publications

(3 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the rapid development of big data research and digital technologies in the recent years, it is anticipated that AI-power big data analytic platforms, coupled with telemedicine, will shape the future landscape of medicine (Sim et al, 2016 ; Ting et al, 2019a ; Wu et al, 2019 ). The need for these innovative digital technologies in clinical practice was further heightened by the recent COVID-19 pandemic where all branches of healthcare services, including ophthalmology, have been severely impacted (Babu et al, 2020 ; Ting et al, 2020b , c , 2021f ; Whitelaw et al, 2020 ; Ho et al, 2021 ; Kim et al, 2021 ).…”

Section: Future Directionsmentioning

confidence: 99%

Big data in corneal diseases and cataract: Current applications and future directions

et al. 2023

View full text Add to dashboard Cite

The accelerated growth in electronic health records (EHR), Internet-of-Things, mHealth, telemedicine, and artificial intelligence (AI) in the recent years have significantly fuelled the interest and development in big data research. Big data refer to complex datasets that are characterized by the attributes of “5 Vs”—variety, volume, velocity, veracity, and value. Big data analytics research has so far benefitted many fields of medicine, including ophthalmology. The availability of these big data not only allow for comprehensive and timely examinations of the epidemiology, trends, characteristics, outcomes, and prognostic factors of many diseases, but also enable the development of highly accurate AI algorithms in diagnosing a wide range of medical diseases as well as discovering new patterns or associations of diseases that are previously unknown to clinicians and researchers. Within the field of ophthalmology, there is a rapidly expanding pool of large clinical registries, epidemiological studies, omics studies, and biobanks through which big data can be accessed. National corneal transplant registries, genome-wide association studies, national cataract databases, and large ophthalmology-related EHR-based registries (e.g., AAO IRIS Registry) are some of the key resources. In this review, we aim to provide a succinct overview of the availability and clinical applicability of big data in ophthalmology, particularly from the perspective of corneal diseases and cataract, the synergistic potential of big data, AI technologies, internet of things, mHealth, and wearable smart devices, and the potential barriers for realizing the clinical and research potential of big data in this field.

show abstract

Section: Future Directionsmentioning

confidence: 99%

Big data in corneal diseases and cataract: Current applications and future directions

et al. 2023

View full text Add to dashboard Cite

show abstract

“…5 . Guidance for virtual consultations is already available and could become embedded into teleophthalmology triaging [ 68 ]. Evolution of teleophthalmology to adequately address dry eye disease may require use of traditional diagnostics like Schirmer’s test or fluorescein break-up time, or adoption of new technologies like InflammaDry® (Quidel; San Diego, California, USA), TearLab® Osmolarity System (TearLab; Escondido, California, USA), Keratograph® 5M (Oculus Optikgeräte; Wetzlar, Germany), Idra ocular surface analyzer (SBM Systemi; Turin, Italy) LipiScan® and LipiView II® (Johnson & Johnson Vision Care; Jacksonville FL, USA) at Primary Eyecare Companies and optometric practices.…”

Section: Recent Innovations and Future Opportunitiesmentioning

confidence: 99%

Achieving net-zero in the dry eye disease care pathway

Latham,

Williams,

Grover

et al. 2023

Eye

View full text Add to dashboard Cite

Climate change is a threat to human health and wellbeing across the world. In recent years, there has been a surge in awareness of this crisis, leading to many countries and organisations setting “net-zero” targets. This entails minimising carbon emissions and neutralising remaining emissions by removing carbon from the atmosphere. At the 2022 United Nations Climate Change Conference (COP27), commitments to transition away from fossil fuels and augment climate targets were underwhelming. It is therefore imperative for public and private sector organisations to demonstrate successful implementation of net-zero and set a precedent for the global political consensus. As a top 10 world employer, the United Kingdom National Health Service (NHS) has pledged to reach net-zero by 2045. The NHS has already taken positive steps forward, but its scale and complexity as a health system means stakeholders in each of its services must highlight the specifications for further progress. Dry eye disease is a chronic illness with an estimated global prevalence of 29.5% and an environmentally damaging care pathway. Moreover, environmental damage is a known aggravator of dry eye disease. Worldwide management of this illness generates copious amounts of non-recyclable waste, utilises inefficient supply chains and involves recurrent follow-up appointments and prescriptions. By mapping the dry eye disease care pathway to environmental impact, in this review we will highlight seven key areas in which reduced emissions and pollution could be targeted. Examining these approaches for improved environmental sustainability is critical in driving the transformation needed to preserve our health and wellbeing.

show abstract

“…In addition, tele-medicine has been explored and implemented to assess and diagnose various corneal diseases, including IK [ [186] , [187] , [188] ]. For instance, Maamari et al [ 186 ] reported the use of a tele-medicine platform in diagnosing corneal epithelial defect and IK based on white and fluorescein images captured by mobile phone.…”

Section: Future Directionsmentioning

confidence: 99%

Diagnostic armamentarium of infectious keratitis: A comprehensive review

et al. 2022

View full text Add to dashboard Cite

Infectious keratitis (IK) represents the leading cause of corneal blindness worldwide, particularly in developing countries. A good outcome of IK is contingent upon timely and accurate diagnosis followed by appropriate interventions. Currently, IK is primarily diagnosed on clinical grounds supplemented by microbiological investigations such as microscopic examination with stains, and culture and sensitivity testing. Although this is the most widely accepted practice adopted in most regions, such an approach is challenged by several factors, including indistinguishable clinical features shared among different causative organisms, polymicrobial infection, long diagnostic turnaround time, and variably low culture positivity rate. In this review, we aim to provide a comprehensive overview of the current diagnostic armamentarium of IK, encompassing conventional microbiological investigations, molecular diagnostics (including polymerase chain reaction and mass spectrometry), and imaging modalities (including anterior segment optical coherence tomography and in vivo confocal microscopy). We also highlight the potential roles of emerging technologies such as next-generation sequencing, artificial intelligence-assisted platforms. and tele-medicine in shaping the future diagnostic landscape of IK.

show abstract

Virtual consultation for red eye

Abstract: What you need to knowThis is part of a series of occasional articles on common problems in primary care. The BMJ welcomes contributions from GPs.

Cited by 5 publications

References 22 publications

Big data in corneal diseases and cataract: Current applications and future directions

Big data in corneal diseases and cataract: Current applications and future directions

Achieving net-zero in the dry eye disease care pathway

Diagnostic armamentarium of infectious keratitis: A comprehensive review

Contact Info

Product

Resources

About